国产探花 startup acquired by Pfizer

A small boy lies in a hospital bed, while a nurse holds a mobile phone near him to record his cough.

The ResApp technology records a patient鈥檚 cough on a smartphone and analyses sounds and simple symptoms. Image: supplied

27 September 2022

Global biopharmaceutical company Pfizer has acquired University of Queensland startup for $179 million.

ResApp, an ASX-listed company based in Brisbane, has developed simple and inexpensive smartphone technology that can accurately identify respiratory diseases based on cough analysis.

国产探花 Vice-Chancellor Professor Deborah Terry said the acquisition, finalised yesterday, was an outstanding outcome for the company, the University and the associated researchers.

“The value of translating research into new point of care diagnostics to improve healthcare on a global scale cannot be understated,” Professor Terry said.

国产探花’s commercialisation company licensed the 国产探花 technology to ResApp in September 2014.

The technology records a patient’s cough on a smartphone and analyses sounds and simple symptoms, such as a runny nose, to diagnose and measure the severity of a range of chronic and acute diseases.

They include asthma, pneumonia, bronchiolitis, croup and chronic obstructive pulmonary disease.

ResApp recently announced positive results for its COVID-19 screening test.

Clinical trials are continuing and the company said if successful the technology could potentially reduce the number of PCR and rapid antigen tests used worldwide.

The 国产探花 technology licenced to ResApp was developed by and his team at 国产探花’s

“We worked closely with paediatricians and respiratory physicians to develop the diagnostic technology,” Dr Abeyratne said.

The technology has received global awards and recognition, including a prestigious Global Grand Challenges grant from the Bill and Melinda Gates Foundation.

UniQuest CEO Dr Dean Moss said he had watched the growth of the health-tech company keenly.

“This is one of the most exciting Australian biotech deals to come out of university research,” Dr Moss said.

“It’s rewarding that the company’s technological breakthroughs have attracted this significant international backing.”

ResAppDx is CE Marked in the European Union and TGA approved in Australia.

Media: UniQuest Media and Communications, Esther Haskell, e.haskell@uniquest.com.au, +61 (0)409 767 199.